Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.480 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday ↗

January 27, 2025

Via Benzinga

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies ↗

January 22, 2025

Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.

Via Benzinga

Topics Government

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗

January 22, 2025

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Via Benzinga

13 Analysts Have This To Say About Intellia Therapeutics ↗

January 13, 2025

Via Benzinga

Peering Into Intellia Therapeutics's Recent Short Interest ↗

January 10, 2025

Via Benzinga

Peering Into Intellia Therapeutics's Recent Short Interest ↗

December 24, 2024

Via Benzinga

9 Analysts Have This To Say About Intellia Therapeutics ↗

November 11, 2024

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce ↗

January 11, 2025

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

Via Benzinga

Topics Workforce

Why Is Intellia Therapeutics Stock Trading Lower On Friday? ↗

January 10, 2025

Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership changes, and prepares for commercialization.

Via Benzinga

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

A Glimpse of Intellia Therapeutics's Earnings Potential ↗

November 06, 2024

Via Benzinga

Looking Into Intellia Therapeutics's Recent Short Interest ↗

October 29, 2024

Via Benzinga

7 Analysts Have This To Say About Intellia Therapeutics ↗

October 25, 2024

Via Benzinga

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? ↗

November 22, 2024

Via The Motley Fool

From GLD To TSLA: Unlocking Today’s Best Trading Opportunities ↗

November 18, 2024

The week kicks off amidst significant market movements shaped by geopolitical and policy developments.

Via Talk Markets

Topics Stocks / Equities

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

November 18, 2024

Via Benzinga

3 Fast-Growing Stocks Analysts See Doubling in Price

November 11, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

Via MarketBeat

A Closer Look at Intellia Therapeutics's Options Market Dynamics ↗

October 24, 2024

Via Benzinga

3 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 24, 2024

Via Benzinga

Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts ↗

September 11, 2024

Via Benzinga

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? ↗

November 06, 2024

There's nothing bearish at all about what it reported recently.

Via The Motley Fool

This Beaten-Down Stock Could Soar by 354%, According to Wall Street ↗

November 04, 2024

Maybe the Street is a bit too optimistic on this one.

Via The Motley Fool

12 High-Growth Stocks That Could Deliver Parabolic Returns ↗

October 28, 2024

These 12 innovative companies could deliver exponential returns over the next quarter century.

Via The Motley Fool

Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 24, 2024

The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.

Via Benzinga

Topics Stocks

Why Intellia Therapeutics Stock Plummeted by 20% Today ↗

October 24, 2024

Seemingly encouraging results from the lab were met with some notable skepticism.

Via The Motley Fool

Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? ↗

October 24, 2024

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Via Benzinga

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street ↗

October 17, 2024

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

Via The Motley Fool

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street ↗

October 09, 2024

These stocks haven't performed well this year.

Via The Motley Fool

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk ↗

September 29, 2024

The Ark Invest portfolio is known for taking aggressive bets.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today